Abstract: The rapid development of medicine has improved the survival rate and survival time of women with malignant tumors. More and more women with malignant tumors are experiencing either natural menopause or premature ovarian insufficiency (POI) due to the side effects of tumor therapy. Estrogen deficiency causes a series of perimenopausal symptoms such as hot flashes, sweating, insomnia, and urogenital tract atrophy, as well as long-term negative risks of cardiovascular disease and osteoporosis, which seriously affect women's quality of life. Therefore, the application of menopausal hormone therapy (MHT) in female malignant tumor survivors was increasingly concerned. Therefore, we evaluated the benefits and risks of MHT in female malignant tumor survivors in this review.